Inderes illustration

Connecting investors and companies

Inderes is a hub connecting investors and listed companies. We are home to over 70 000 investors and 400 Nordic listed companies. Log in to keep up with your favourite companies!

 
OMXSPI+0.16%
OMXS30+0.05%
OMXHPI+1.54%
INCOAX+72.82%
ONCO+38.71%
EASY B+35.42%
CI-25.10%
KVIX-25.88%
S2M-31.25%
 
 

Next up today

 
Ascelia Pharma: Video presentation of the Q1 2026 results
Analyst Comment by

Ascelia Pharma: Video presentation of the Q1 2026 results

Yesterday, we hosted an event with Magnus Corfitzen, CEO of Ascelia Pharma. The presentation focused on the financial results and regulatory milestones achieved during the first quarter, with particular emphasis on the investment case for Orviglance. The event concluded with a Q&A session, with discussion centered on the status and outlook regarding potential partners and the upcoming potential approval of Orviglance.

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Wirtek: Recording of Q1 2026 results presentation
Analyst Comment by

Wirtek: Recording of Q1 2026 results presentation

Today, Wirtek’s CEO Michael Aaen and CFO Mads Greiffenberg presented the company’s Q1 2026 results , and what is driving the increased profitability despite muted topline growth The presentation was followed by a Q&A session.

Gubra (One-pager): A clinically pivotal quarter, with two obesity assets advancing toward Phase 2
Research by

Gubra (One-pager): A clinically pivotal quarter, with two obesity assets advancing toward Phase 2

We have updated our One-pager investment case on Gubra to reflect the Q1 2026 trading statement, the revised CRO guidance, and the clinical newsflow across the pipeline. The quarter has incrementally strengthened the D&P-driven equity value case, while the CRO downgrade has only a limited impact on our valuation framework given the segment's modest share of total enterprise value.